Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Malaseb is a veterinary topical antimicrobial and antifungal skin-care product line combining chlorhexidine gluconate and miconazole nitrate for dogs, cats, and horses. It is formulated as a medicated shampoo, spray, and flush to treat or support management of seborrhoeic dermatitis and other bacterial, yeast, and dermatophyte-associated skin diseases, including infections caused by Malassezia pachydermatis, Staphylococcus intermedius, and Microsporum canis.[3][4][5][6][8][11][14] Chlorhexidine provides broad-spectrum bactericidal activity against gram-positive and gram-negative organisms, while miconazole disrupts fungal cell membranes to control yeasts and dermatophytes, and the formulations may include emollients, essential fatty acids, and vitamin E to support skin barrier function and hydration.[1][2][3][9][11][14] Malaseb is marketed as an Rx-only or veterinary product and is commonly used under veterinary supervision as part of topical therapy protocols for dermatologic disease in companion animals.[3][5][8][10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Malaseb.